Background
Repetitive transcranial magnetic stimulation (rTMS) is a non-invasive brain stimulation technique that can be used to target neuronal circuitry implicated in neuropsychiatric disorders, such as the dorsolateral prefrontal cortex (DLPFC) in depression. rTMS has been reported to be as effective as electroconvulsive therapy (ECT), which is currently the most powerful treatment available for severe depression.
Objective
The aim of this study was to investigate if rTMS was as effective as ECT in treating major depressive episodes and to perform a costeffectiveness analysis.
Methods

Design
The study was a single-blind pragmatic multicentre randomised controlled trial (RCT) with 6 months of follow-up to test equivalence of rTMS with ECT.
Setting
The study took place in the South London and Maudsley NHS Trust and Pembury Hospital in the Invicta Mental Health Trust in Kent.
Participants
Right-handed adult patients referred for ECT for treatment of a major depressive episode (DSM-IV) were assessed. During the 2.5-year trial period, 260 patients were referred for ECT, of whom 46 entered the trial. The main reason for not entering the trial was not consenting to ECT while being formally treated under the UK Mental Health Act 1983.
Interventions
Patients were randomised to receive a 15-day course of rTMS of the left DLPFC (n = 24; 20 trains per day, 5 seconds of treatment at 10 Hz, 110% of motor threshold) or a course of ECT (n = 22; stimulus dosing method, 1.5 times the seizure threshold, course length decided by referring physician).
Main outcome measures
Patients were assessed before randomisation, at end of treatment and at the 6-month follow-up. Primary outcome measures were the 17-item Hamilton Rating Scale for Depression (HRSD) and proportion of remitters (defined as HRSD score р8) at the end-of-treatment time point. Secondary outcomes included self-ratings for mood on the Beck Depression Inventory-II (BDI-II) and visual analogue mood scales (VAMS), the Brief Psychiatric Rating Scale (BPRS), plus subjective and objective side-effects. Low scores on the BDI-II, VAMS and BPRS are positive in terms of health. The results were analysed on an intention-to-treat basis. Cost data were collected using the Client Service Receipt Inventory and the Short Form with 36 Items (SF-36) was used to obtain quality of life measures. Health economic outcomes were cost of treatments, costs incurred during the 6-month follow-up period and gains in quality-adjusted lifeyears (QALYs).
Data analysis
HRSD and other clinical outcome scores were compared between groups using an analysis of covariance (ANCOVA) model with baseline scores as covariates. Trial data that became available before recruitment began allowed revision of samples sizes such that 22 subjects per treatment group would be sufficient to have 80% power to demonstrate, using a one-sided equivalence test at the ␣ = 0.5 level, that the mean reduction in HDRS score using rTMS would be no more than 25% less than that achieved using ECT.
Results
One patient was lost to follow-up at end of treatment and another eight at 6 months. The end-of-treatment HRSD scores were lower for ECT [95% confidence interval (CI) 3.40 to 14.05, p = 0.002], with 13 (59%) achieving remission compared with four (17%) in the rTMS group ( p = 0.005). However, HRSD scores did not differ
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Executive summary between groups at 6 months. BDI-II, VAMS and BPRS scores were lower for ECT at end of treatment and remained lower after 6 months. Improvement in subjective reports of side-effects following ECT correlated with antidepressant response. There was no difference between the two groups before or after treatment on global measures of cognition.
Although individual treatment session costs were lower for rTMS than ECT, the cost for a course of rTMS was not significantly different from that for a course of ECT as more rTMS sessions were given per course. Service costs were not different between the groups in the subsequent 6 months but informal care costs were significantly higher for the rTMS group ( p = 0.04) and contributed substantially to the total cost for this group during the 6-month follow-up period. There was also no difference in gain in QALYs for ECT and rTMS patients. Analysis of cost-effectiveness acceptability curves demonstrated that rTMS has very low probability of being more cost-effective than ECT.
Limitations
Rater blinding was not maintained and is a potential source of bias. However, similar results were obtained on both observer-and self-rated measures. The optimal parameters for administering rTMS to achieve an antidepressant effect are not yet known.
Conclusions
ECT is a more effective and potentially costeffective antidepressant treatment than 3 weeks of rTMS as administered in this study. Optimal treatment parameters for rTMS need to be established for treating depression. More research is required to refine further the administration of ECT in order to reduce associated cognitive sideeffects while maintaining its effectiveness.
Recommendations for further research
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